SG11202012045UA - Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione - Google Patents
Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dioneInfo
- Publication number
- SG11202012045UA SG11202012045UA SG11202012045UA SG11202012045UA SG11202012045UA SG 11202012045U A SG11202012045U A SG 11202012045UA SG 11202012045U A SG11202012045U A SG 11202012045UA SG 11202012045U A SG11202012045U A SG 11202012045UA SG 11202012045U A SG11202012045U A SG 11202012045UA
- Authority
- SG
- Singapore
- Prior art keywords
- thiazolidine
- dione
- pyridin
- ethoxy
- hydroxyethyl
- Prior art date
Links
- OXVFDZYQLGRLCD-UHFFFAOYSA-N hydroxypioglitazone Chemical compound N1=CC(C(O)C)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 OXVFDZYQLGRLCD-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382398 | 2018-06-06 | ||
| PCT/IB2019/054743 WO2019234689A1 (en) | 2018-06-06 | 2019-06-06 | Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202012045UA true SG11202012045UA (en) | 2021-01-28 |
Family
ID=62716009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012045UA SG11202012045UA (en) | 2018-06-06 | 2019-06-06 | Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210308113A1 (https=) |
| EP (1) | EP3801516A1 (https=) |
| JP (1) | JP7549344B2 (https=) |
| KR (1) | KR20210031435A (https=) |
| CN (1) | CN112512524A (https=) |
| AU (1) | AU2019283649A1 (https=) |
| BR (1) | BR112020024917A2 (https=) |
| CA (1) | CA3102407A1 (https=) |
| CL (1) | CL2020003162A1 (https=) |
| EA (1) | EA202092953A1 (https=) |
| IL (1) | IL279183A (https=) |
| MX (1) | MX2020013181A (https=) |
| SG (1) | SG11202012045UA (https=) |
| WO (1) | WO2019234689A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| EP3801515B1 (en) | 2018-06-06 | 2025-04-09 | Minoryx Therapeutics S.L. | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases |
| EP4642456A1 (en) | 2022-12-28 | 2025-11-05 | Minoryx Therapeutics S.L. | Optimized dosing of leriglitazone |
| WO2024231881A2 (en) | 2023-05-09 | 2024-11-14 | Minoryx Therapeutics S.L. | Polymorphic forms and formulations of leriglitazone |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009517186A (ja) | 2005-11-29 | 2009-04-30 | チルドレンズ ホスピタル メディカル センター | 薬物選択及び投薬の最適化及び個別化 |
| US20140114676A1 (en) * | 2012-10-23 | 2014-04-24 | Theranos, Inc. | Drug Monitoring and Regulation Systems and Methods |
| EA202091120A3 (ru) * | 2014-04-02 | 2020-12-30 | Минорикс Терапьютикс С.Л. | Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы |
| ES2926580T3 (es) | 2016-12-23 | 2022-10-27 | Minoryx Therapeutics S L | Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil]etoxi]fenil]metil]-2,4-tiazolidindiona y sales de la misma |
-
2019
- 2019-06-06 CN CN201980046617.8A patent/CN112512524A/zh active Pending
- 2019-06-06 BR BR112020024917-3A patent/BR112020024917A2/pt not_active Application Discontinuation
- 2019-06-06 AU AU2019283649A patent/AU2019283649A1/en not_active Abandoned
- 2019-06-06 US US16/972,368 patent/US20210308113A1/en active Pending
- 2019-06-06 JP JP2020567799A patent/JP7549344B2/ja active Active
- 2019-06-06 EP EP19742912.9A patent/EP3801516A1/en active Pending
- 2019-06-06 SG SG11202012045UA patent/SG11202012045UA/en unknown
- 2019-06-06 KR KR1020207037943A patent/KR20210031435A/ko not_active Abandoned
- 2019-06-06 WO PCT/IB2019/054743 patent/WO2019234689A1/en not_active Ceased
- 2019-06-06 EA EA202092953A patent/EA202092953A1/ru unknown
- 2019-06-06 MX MX2020013181A patent/MX2020013181A/es unknown
- 2019-06-06 CA CA3102407A patent/CA3102407A1/en active Pending
-
2020
- 2020-12-03 IL IL279183A patent/IL279183A/en unknown
- 2020-12-04 CL CL2020003162A patent/CL2020003162A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL279183A (en) | 2021-01-31 |
| BR112020024917A2 (pt) | 2021-03-09 |
| JP2021527045A (ja) | 2021-10-11 |
| EA202092953A1 (ru) | 2021-04-12 |
| US20210308113A1 (en) | 2021-10-07 |
| AU2019283649A1 (en) | 2021-01-07 |
| CN112512524A (zh) | 2021-03-16 |
| EP3801516A1 (en) | 2021-04-14 |
| WO2019234689A1 (en) | 2019-12-12 |
| JP7549344B2 (ja) | 2024-09-11 |
| KR20210031435A (ko) | 2021-03-19 |
| CA3102407A1 (en) | 2019-12-12 |
| MX2020013181A (es) | 2021-02-26 |
| CL2020003162A1 (es) | 2021-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279183A (en) | Method for administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1, 3-thiazolidine-2, 4-dione | |
| CY1125531T1 (el) | Μεθοδος παρασκευης της 5-[[4-[2-[5-(1- υδροξυαιθυλ)-2-πυριδι-νυλ]αιθοξυ]φαινυλ]μεθυλ]- 2,4-θειαζολιδινεδιονη και των αλατων της | |
| IL279186A (en) | Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1, 3-thiazolidine-2, 4-dione and their salts | |
| LT3548026T (lt) | 5-[[4-[2-[5-(1-hidroksietil)piridin-2-il]etoksi]fenil]metil]-1,3-tiazolidin-2,4-dionas nealkoholinio kepenų suriebėjimo gydymui | |
| WO2012047966A4 (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
| RU2011133833A (ru) | Способы лечения синдрома сосудистой утечки | |
| JP2014528486A5 (https=) | ||
| RU2018138707A (ru) | Замещенные гетероарилом пиридины и способы применения | |
| WO2005080358A3 (en) | Rosiglitazone phosphate and polymorphic forms | |
| FI3511319T3 (fi) | Lysiinispesifisen demetylaasi-1:n inhibiittoreita | |
| JP2013516483A5 (https=) | ||
| WO2009015812A3 (de) | Prodrugs des 2-amino-6- ( { [2- (4-chlorphenyl) -1, 3-thiaz0l-4-yl] methyl}thio) -4- [4- ( 2 -hydroxyethoxy) phenyl] pyridin-3, 5-dicarbonitrils | |
| PL3801515T3 (pl) | 5-[[4-[2-[5-(1-hydroksyetylo)pirydyn-2-ylo]etoksy]fenylo]metylo]-1,3-tiazolidyno-2,4-dion i jego sole do zastosowania w leczeniu chorób mitochondrialnych | |
| SI3038622T1 (en) | Heterocyclic compounds and methods of use | |
| NZ629636A (en) | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions | |
| MX2022013021A (es) | Leriglitazona para tratar inflamacion pulmonar y enfermedad pulmonar intersticial. | |
| RU2015126293A (ru) | Производные тиазола в качестве ингибиторов тирозинкиназы брутона | |
| HK40050840A (en) | Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione | |
| IL188175A0 (en) | 2-n-(5-[[4-(2-methyl-2-pyridinylamino)ethoxy] phenyl] methyl]-2,4-thiazolidinedione)butanedioic acid, methods of preparation and compositions with rosiglitazone maleate | |
| AU2003269483A1 (en) | Phosphoric acid salt of 5-((4-(2-(methyl-2-pyridinylamino) ethoxy) phenyl) methyl)- 2,4-thiazolidinedione | |
| HK40131421A (en) | Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide | |
| PL385697A1 (pl) | Sól 5-[[4-[2-(metylo-2-pirydynyloamino)etoksy]fenylo]metylo]-2, 4-tiazolidynodionu z kwasem 1, 5-naftalenodisulfonowym i sposób jej wytwarzania | |
| NZ599855A (en) | Carboxy oxazole or thiazole compounds as dgat - 1 inhibitors useful for the treatment of obesity | |
| HK40025190A (en) | Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide |